A peptide corresponding to positions 62-71 of the sequence of human C-reactive protein (CRP) of the formula: Glu
62
-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile
71
and modifications thereof obtained by substitution, deletion, or addition of amino acids, amidation of the C-terminal or acylation of the N-terminal, are capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG) and can be used for the treatment of chronic inflammation conditions such as rheumatoid arthritis, pulmonary emphysema, cystic fibrosis, bronchitis, asthma and some acute respiratory distress syndrome.
与人 C 反应蛋白(CRP)序列第 62-71 位相对应的
多肽,其分子式为Glu
62
-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile
71
及其通过
氨基酸的替换、缺失或添加、C-末端的酰胺化或 N-末端的酰化而得到的修饰,能够在体外抑制人白细胞
弹性蛋白酶(hLE)和/或人
酪蛋白酶 G(hCG)的酶活性,可用于治疗慢性炎症,如类风湿性关节炎、肺气肿、囊性纤维化、支气管炎、哮喘和某些急性呼吸窘迫综合征。